Amgen Inc., the first Leadership-level campaign donor, has also been an integral supporter of the Foundation’s awards and grants program. “Amgen is dedicated to supporting and empowering healthcare providers who will be on the frontlines of treating patients with rheumatic diseases,” says Daniel Billen, vice president and general manager, Inflammation and Nephrology, Amgen. “We are proud that through our commitment to the Foundation, we are able to help advance the rheumatology community’s knowledge and ultimately help improve the care of patients living with these diseases.”
Another Leadership-level campaign donor, Pfizer Inc., has increased its investment in the Foundation over the years. “At Pfizer, we believe in the value of investing in emerging areas of science and developing innovative therapies for those in greatest need, especially those suffering with chronic inflammatory conditions,” says Andrew Koenig, medical director, Inflammation and Immunology, Pfizer. “It is our goal to partner with the global healthcare community, including organizations like the Rheumatology Research Foundation, to help improve patient outcomes. We hope that the Foundation’s awards will help identify best practices, persistent treatment gaps and actionable processes that can result in an overall improvement in patient care.”
For those affected by rheumatic diseases, the Foundation’s awards provide hope for improved health. Melissa Young, who has rheumatoid arthritis, says, “It’s tangible what the Foundation is doing. They’re actually showing strides and steps in a direction toward finding better solutions, and, ultimately, a cure.”
Learn more about the exciting work being done by the latest recipients of Foundation funding.
